Gene symbol: DBH

Also known as: DBM; ORTHYP1

Organism: Homo sapiens

Summary: The protein encoded by this gene is an oxidoreductase belonging to the copper type II, ascorbate-dependent monooxygenase family. The encoded protein, expressed in neuroscretory vesicles and chromaffin granules of the adrenal medulla, catalyzes the conversion of dopamine to norepinephrine, which functions as both a hormone and as the main neurotransmitter of the sympathetic nervous system. The enzyme encoded by this gene exists exists in both soluble and membrane-bound forms, depending on the absence or presence, respectively, of a signal peptide. Mutations in this gene cause dopamine beta-hydroxylate deficiency in human patients, characterized by deficits in autonomic and cardiovascular function, including hypotension and ptosis. Polymorphisms in this gene may play a role in a variety of psychiatric disorders. [provided by RefSeq, Aug 2017]

NCBI gene ID: 1621 Ensembl:ENSG00000123454 MIM:609312 AllianceGenome:HGNC:2689


GO Annotation


Category Term ID Term description
Process GO:0000003 Reproduction
Process GO:0001505 Regulation of neurotransmitter levels
Process GO:0001659 Temperature homeostasis
Process GO:0001936 Regulation of endothelial cell proliferation
Process GO:0001974 Blood vessel remodeling
Process GO:0001975 Response to amphetamine
Process GO:0002252 Immune effector process
Process GO:0002376 Immune system process
Process GO:0002443 Leukocyte mediated immunity
Process GO:0003008 System process
Process GO:0003013 Circulatory system process
Process GO:0003018 Vascular process in circulatory system
Process GO:0006066 Alcohol metabolic process
Process GO:0006576 Cellular biogenic amine metabolic process
Process GO:0006584 Catecholamine metabolic process
Process GO:0006589 Octopamine biosynthetic process
Process GO:0006725 Cellular aromatic compound metabolic process
Process GO:0006807 Nitrogen compound metabolic process
Process GO:0006950 Response to stress
Process GO:0007154 Cell communication
Process GO:0007267 Cell-cell signaling
Process GO:0007268 Chemical synaptic transmission
Process GO:0007610 Behavior
Process GO:0007611 Learning or memory
Process GO:0007612 Learning
Process GO:0007613 Memory
Process GO:0007626 Locomotory behavior
Process GO:0007632 Visual behavior
Process GO:0008015 Blood circulation
Process GO:0008152 Metabolic process
Process GO:0008306 Associative learning
Process GO:0008542 Visual learning
Process GO:0009056 Catabolic process
Process GO:0009058 Biosynthetic process
Process GO:0009308 Amine metabolic process
Process GO:0009309 Amine biosynthetic process
Process GO:0009310 Amine catabolic process
Process GO:0009314 Response to radiation
Process GO:0009416 Response to light stimulus
Process GO:0009628 Response to abiotic stimulus
Process GO:0009712 Catechol-containing compound metabolic process
Process GO:0009713 Catechol-containing compound biosynthetic process
Process GO:0009893 Positive regulation of metabolic process
Process GO:0009966 Regulation of signal transduction
Process GO:0009987 Cellular process
Process GO:0010033 Response to organic substance
Process GO:0010243 Response to organonitrogen compound
Process GO:0010646 Regulation of cell communication
Process GO:0010941 Regulation of cell death
Process GO:0014075 Response to amine
Process GO:0016477 Cell migration
Process GO:0018958 Phenol-containing compound metabolic process
Process GO:0019098 Reproductive behavior
Process GO:0019222 Regulation of metabolic process
Process GO:0019229 Regulation of vasoconstriction
Process GO:0019336 Phenol-containing compound catabolic process
Process GO:0019438 Aromatic compound biosynthetic process
Process GO:0019439 Aromatic compound catabolic process
Process GO:0019614 Catechol-containing compound catabolic process
Process GO:0022414 Reproductive process
Process GO:0023051 Regulation of signaling
Process GO:0023052 Signaling
Process GO:0030534 Adult behavior
Process GO:0032501 Multicellular organismal process
Process GO:0032504 Multicellular organism reproduction
Process GO:0033500 Carbohydrate homeostasis
Process GO:0033555 Multicellular organismal response to stress
Process GO:0034641 Cellular nitrogen compound metabolic process
Process GO:0035150 Regulation of tube size
Process GO:0035296 Regulation of tube diameter
Process GO:0042127 Regulation of cell population proliferation
Process GO:0042133 Neurotransmitter metabolic process
Process GO:0042136 Neurotransmitter biosynthetic process
Process GO:0042221 Response to chemical
Process GO:0042309 Homoiothermy
Process GO:0042310 Vasoconstriction
Process GO:0042401 Cellular biogenic amine biosynthetic process
Process GO:0042402 Cellular biogenic amine catabolic process
Process GO:0042415 Norepinephrine metabolic process
Process GO:0042417 Dopamine metabolic process
Process GO:0042420 Dopamine catabolic process
Process GO:0042421 Norepinephrine biosynthetic process
Process GO:0042423 Catecholamine biosynthetic process
Process GO:0042424 Catecholamine catabolic process
Process GO:0042439 Ethanolamine-containing compound metabolic process
Process GO:0042592 Homeostatic process
Process GO:0042593 Glucose homeostasis
Process GO:0042596 Fear response
Process GO:0042711 Maternal behavior
Process GO:0042981 Regulation of apoptotic process
Process GO:0043067 Regulation of programmed cell death
Process GO:0044057 Regulation of system process
Process GO:0044106 Cellular amine metabolic process
Process GO:0044237 Cellular metabolic process
Process GO:0044248 Cellular catabolic process
Process GO:0044249 Cellular biosynthetic process
Process GO:0044271 Cellular nitrogen compound biosynthetic process
Process GO:0044281 Small molecule metabolic process
Process GO:0044283 Small molecule biosynthetic process
Process GO:0045471 Response to ethanol
Process GO:0045907 Positive regulation of vasoconstriction
Process GO:0046165 Alcohol biosynthetic process
Process GO:0046189 Phenol-containing compound biosynthetic process
Process GO:0046333 Octopamine metabolic process
Process GO:0048149 Behavioral response to ethanol
Process GO:0048265 Response to pain
Process GO:0048518 Positive regulation of biological process
Process GO:0048583 Regulation of response to stimulus
Process GO:0048609 Multicellular organismal reproductive process
Process GO:0048660 Regulation of smooth muscle cell proliferation
Process GO:0048771 Tissue remodeling
Process GO:0048870 Cell motility
Process GO:0048871 Multicellular organismal homeostasis
Process GO:0048878 Chemical homeostasis
Process GO:0050678 Regulation of epithelial cell proliferation
Process GO:0050789 Regulation of biological process
Process GO:0050794 Regulation of cellular process
Process GO:0050877 Nervous system process
Process GO:0050890 Cognition
Process GO:0050896 Response to stimulus
Process GO:0050900 Leukocyte migration
Process GO:0051239 Regulation of multicellular organismal process
Process GO:0051240 Positive regulation of multicellular organismal process
Process GO:0060746 Parental behavior
Process GO:0065007 Biological regulation
Process GO:0065008 Regulation of biological quality
Process GO:0071704 Organic substance metabolic process
Process GO:0090066 Regulation of anatomical structure size
Process GO:0097305 Response to alcohol
Process GO:0097746 Blood vessel diameter maintenance
Process GO:0098916 Anterograde trans-synaptic signaling
Process GO:0099536 Synaptic signaling
Process GO:0099537 Trans-synaptic signaling
Process GO:0120161 Regulation of cold-induced thermogenesis
Process GO:0120162 Positive regulation of cold-induced thermogenesis
Process GO:1901360 Organic cyclic compound metabolic process
Process GO:1901361 Organic cyclic compound catabolic process
Process GO:1901362 Organic cyclic compound biosynthetic process
Process GO:1901564 Organonitrogen compound metabolic process
Process GO:1901565 Organonitrogen compound catabolic process
Process GO:1901566 Organonitrogen compound biosynthetic process
Process GO:1901575 Organic substance catabolic process
Process GO:1901576 Organic substance biosynthetic process
Process GO:1901615 Organic hydroxy compound metabolic process
Process GO:1901616 Organic hydroxy compound catabolic process
Process GO:1901617 Organic hydroxy compound biosynthetic process
Process GO:1901698 Response to nitrogen compound
Process GO:1901700 Response to oxygen-containing compound
Process GO:1903522 Regulation of blood circulation
Process GO:1904705 Regulation of vascular associated smooth muscle cell proliferation
Process GO:1905562 Regulation of vascular endothelial cell proliferation
Process GO:2001233 Regulation of apoptotic signaling pathway
Process GO:2001236 Regulation of extrinsic apoptotic signaling pathway
Component GO:0005576 Extracellular region
Component GO:0005615 Extracellular space
Component GO:0005622 Intracellular anatomical structure
Component GO:0005737 Cytoplasm
Component GO:0005783 Endoplasmic reticulum
Component GO:0005813 Centrosome
Component GO:0005815 Microtubule organizing center
Component GO:0005856 Cytoskeleton
Component GO:0012505 Endomembrane system
Component GO:0012506 Vesicle membrane
Component GO:0015630 Microtubule cytoskeleton
Component GO:0016020 Membrane
Component GO:0016021 Integral component of membrane
Component GO:0030054 Cell junction
Component GO:0030133 Transport vesicle
Component GO:0030141 Secretory granule
Component GO:0030658 Transport vesicle membrane
Component GO:0030659 Cytoplasmic vesicle membrane
Component GO:0030667 Secretory granule membrane
Component GO:0031090 Organelle membrane
Component GO:0031224 Intrinsic component of membrane
Component GO:0031410 Cytoplasmic vesicle
Component GO:0031974 Membrane-enclosed lumen
Component GO:0031982 Vesicle
Component GO:0031983 Vesicle lumen
Component GO:0034451 Centriolar satellite
Component GO:0034466 Chromaffin granule lumen
Component GO:0034774 Secretory granule lumen
Component GO:0042583 Chromaffin granule
Component GO:0042584 Chromaffin granule membrane
Component GO:0043226 Organelle
Component GO:0043227 Membrane-bounded organelle
Component GO:0043228 Non-membrane-bounded organelle
Component GO:0043229 Intracellular organelle
Component GO:0043231 Intracellular membrane-bounded organelle
Component GO:0043232 Intracellular non-membrane-bounded organelle
Component GO:0043233 Organelle lumen
Component GO:0045202 Synapse
Component GO:0060205 Cytoplasmic vesicle lumen
Component GO:0070013 Intracellular organelle lumen
Component GO:0097708 Intracellular vesicle
Component GO:0098588 Bounding membrane of organelle
Component GO:0099503 Secretory vesicle
Component GO:0110165 Cellular anatomical entity
Function GO:0003824 Catalytic activity
Function GO:0004497 Monooxygenase activity
Function GO:0004500 Dopamine beta-monooxygenase activity
Function GO:0005488 Binding
Function GO:0005507 Copper ion binding
Function GO:0016491 Oxidoreductase activity
Function GO:0016705 Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
Function GO:0016715 Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced ascorbate as one donor, and incorporation of one atom of oxygen
Function GO:0019842 Vitamin binding
Function GO:0030246 Carbohydrate binding
Function GO:0031406 Carboxylic acid binding
Function GO:0031418 L-ascorbic acid binding
Function GO:0036094 Small molecule binding
Function GO:0043167 Ion binding
Function GO:0043168 Anion binding
Function GO:0043169 Cation binding
Function GO:0043177 Organic acid binding
Function GO:0046872 Metal ion binding
Function GO:0046914 Transition metal ion binding
Function GO:0048029 Monosaccharide binding
Function GO:0097159 Organic cyclic compound binding
Function GO:1901363 Heterocyclic compound binding

Pathway annotation


Category Term ID Term description
RCTM HSA-1430728 Metabolism
RCTM HSA-209776 Metabolism of amine-derived hormones
RCTM HSA-209905 Catecholamine biosynthesis
RCTM HSA-71291 Metabolism of amino acids and derivatives
WikiPathways WP3925 Amino acid metabolism
WikiPathways WP4156 Biosynthesis and regeneration of tetrahydrobiopterin and catabolism of phenylalanine
WikiPathways WP4220 Neurotransmitter disorders
WikiPathways WP5316 Primary ovarian insufficiency
WikiPathways WP550 Biogenic amine synthesis
WikiPathways WP727 Monoamine transport

Expression profile of DBH in omics data



ID GSE101724
Title Effects of Propofol Treatment in Neural Progenitors Derived from Human Induced Pluripotent Stem Cells
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM2714094 untreated rep1 treatment: untreated 7.305462026
GSM2714095 untreated rep2 treatment: untreated 7.325155644
GSM2714096 20 uM propofol rep1 treatment: 20 uM propofol 7.318891873
GSM2714097 20 uM propofol rep2 treatment: 20 uM propofol 7.247310312
GSM2714098 300 uM propofol rep1 treatment: 300 uM propofol 7.228597102
GSM2714099 300 uM propofol rep2 treatment: 300 uM propofol 7.276147433

ID GSE120596
Title Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction is Associated with Differences in Activation of the Cyclooxygenase Pathway
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM3405450 1001_baseline cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: baseline library barcode: ATTACTCG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 5.0
GSM3405451 1001_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: post-surgery 1 library barcode: TCCGGAGA-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 6.0
GSM3405452 1002_baseline cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: baseline library barcode: CGCTCATT-TATAGCCT drug treatment: Placebo response group: Placebo 2.0
GSM3405453 1002_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: post-surgery 1 library barcode: GAGATTCC-TATAGCCT drug treatment: Placebo response group: Placebo 2.0
GSM3405454 1003_baseline cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: baseline library barcode: ATTCAGAA-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder 8.0
GSM3405455 1003_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: post-surgery 1 library barcode: GAATTCGT-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405456 1004_baseline cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: baseline library barcode: CTGAAGCT-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 3.0
GSM3405457 1004_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: post-surgery 1 library barcode: TAATGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder
GSM3405458 1005_baseline cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: baseline library barcode: CGGCTATG-TATAGCCT drug treatment: Placebo response group: Placebo 1.0
GSM3405459 1005_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-TATAGCCT drug treatment: Placebo response group: Placebo
GSM3405460 1006_baseline cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: baseline library barcode: TCTCGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 2.0
GSM3405461 1006_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: post-surgery 1 library barcode: AGCGATAG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405462 1007_baseline cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: baseline library barcode: ATTACTCG-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405463 1007_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: post-surgery 1 library barcode: TCCGGAGA-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405464 1008_baseline cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: baseline library barcode: CGCTCATT-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405465 1008_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405466 1008_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405467 1011_baseline cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: baseline library barcode: GAATTCGT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405468 1011_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405469 1011_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405470 1012_baseline cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: baseline library barcode: CGGCTATG-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405471 1012_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405472 1012_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder
GSM3405473 1014_baseline cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: baseline library barcode: AGCGATAG-ATAGAGGC drug treatment: Placebo response group: Placebo 0.0
GSM3405474 1014_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-CCTATCCT drug treatment: Placebo response group: Placebo 2.0
GSM3405475 1014_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-CCTATCCT drug treatment: Placebo response group: Placebo 1.0
GSM3405476 1015_baseline cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: baseline library barcode: CGCTCATT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 1.0
GSM3405477 1015_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 1.0
GSM3405478 1015_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 3.0
GSM3405479 1016_baseline cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: baseline library barcode: GAATTCGT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405480 1016_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405481 1016_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405482 1017_baseline cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: baseline library barcode: CGGCTATG-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405483 1017_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-CCTATCCT drug treatment: Placebo response group: Placebo 1.0
GSM3405484 1017_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 2 library barcode: TCTCGCGC-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405485 1018_baseline cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: baseline library barcode: AGCGATAG-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 2.0
GSM3405486 1018_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 3.0
GSM3405487 1018_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 1.0
GSM3405488 1019_baseline cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: baseline library barcode: CGCTCATT-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405489 1019_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405490 1019_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405491 1020_baseline cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: baseline library barcode: GAATTCGT-GGCTCTGA drug treatment: Placebo response group: Placebo
GSM3405492 1020_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-GGCTCTGA drug treatment: Placebo response group: Placebo 11.0
GSM3405493 1020_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-GGCTCTGA drug treatment: Placebo response group: Placebo 0.0
GSM3405494 1021_baseline cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: baseline library barcode: CGGCTATG-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405495 1021_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405496 1021_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405497 1022_baseline cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: baseline library barcode: AGCGATAG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 3.0
GSM3405498 1022_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder 1.0
GSM3405499 1022_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405500 1023_baseline cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: baseline library barcode: CGCTCATT-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405501 1023_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405502 1023_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405503 1024_baseline cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: baseline library barcode: GAATTCGT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405504 1024_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405505 1024_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405506 1026_baseline cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: baseline library barcode: CGGCTATG-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405507 1026_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405508 1026_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405509 1027_baseline cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: baseline library barcode: AGCGATAG-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405510 1027_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-TAATCTTA drug treatment: Placebo response group: Placebo 4.0
GSM3405511 1027_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-TAATCTTA drug treatment: Placebo response group: Placebo 2.0
GSM3405512 1028_baseline cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: baseline library barcode: CGCTCATT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405513 1028_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405514 1028_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405515 1029_baseline cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: baseline library barcode: GAATTCGT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405516 1029_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405517 1029_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405518 1030_baseline cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: baseline library barcode: CGGCTATG-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405519 1030_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 2.0
GSM3405520 1030_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 1.0
GSM3405521 1032_baseline cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: baseline library barcode: AGCGATAG-TAATCTTA drug treatment: Placebo response group: Placebo 1.0
GSM3405522 1032_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-CAGGACGT drug treatment: Placebo response group: Placebo 0.0
GSM3405523 1032_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-CAGGACGT drug treatment: Placebo response group: Placebo 1.0
GSM3405524 1033_baseline cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: baseline library barcode: CGCTCATT-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 1.0
GSM3405525 1033_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 1.0
GSM3405526 1033_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 0.0

ID GSE12860
Title Antirheumatic Drug Response in Human Chondrocytes: Potential Molecular Targets to Stimulate Cartilage Regeneration
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM322609 RASF stimulated chondrocytes rep 1 GSM253283 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium 5.672983198
GSM322610 RASF stimulated chondrocytes rep 2 GSM253284 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium 5.189086233
GSM322611 NDSF stimulated chondrocytes rep 1 GSM253285 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of NDSF cultured in the same medium 5.369386443
GSM322612 NDSF stimulated chondrocytes rep 2 GSM253286 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of NDSF cultured in the same medium 5.270785295
GSM322613 Chondrocytes stimulated with diclofenac treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with diclofenac for 48h 5.694343798
GSM322614 Chondrocytes stimulated with diclofenac treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with diclofenac for 48h 5.438366549
GSM322615 Chondrocytes stimulated with prioxicam treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with piroxicam for 48h 5.197760811
GSM322616 Chondrocytes stimulated with prioxicam treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with piroxicam for 48h 5.103333499
GSM322617 Chondrocytes stimulated with chloroquine phosphate (resochin) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with chloroquine phosphate (resochin) for 48h 5.06012444
GSM322618 Chondrocytes stimulated with chloroquine phosphate (resochin) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with chloroquine phosphate (resochin) for 48h 5.595586428
GSM322619 Chondrocytes stimulated with sodium aurothiomalate (tauredon) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with sodium aurothiomalate (tauredon) for 48h 5.738890629
GSM322620 Chondrocytes stimulated with sodium aurothiomalate (tauredon) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with sodium aurothiomalate (tauredon) for 48h 5.501826942
GSM322621 Chondrocytes stimulated with azathioprine (imurek) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with azathioprine (imurek) for 48h 5.56010968
GSM322622 Chondrocytes stimulated with azathioprine (imurek) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with azathioprine (imurek) for 48h 5.419732894
GSM322623 Chondrocytes stimulated with methotrexate treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methotrexate for 48h 5.760707075
GSM322624 Chondrocytes stimulated with methotrexate treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methotrexate for 48h 5.49348805
GSM322625 Chondrocytes stimulated with prednisolone (solu-decortin) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with prednisolone (solu-decortin) for 48h 5.463114813
GSM322626 Chondrocytes stimulated with prednisolone (solu-decortin) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with prednisolone (solu-decortin) for 48h 5.626614338
GSM322627 Chondrocytes stimulated with methylprednisolone (urbason) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methylprednisolone (urbason) for 48h 5.052221252
GSM322628 Chondrocytes stimulated with methylprednisolone (urbason) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methylprednisolone (urbason) for 48h 5.406277624

ID GSE150408
Title Identification of key genes potentially related to intervertebral disc degeneration by microarray analysis
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM4548691 volunteer-9 tissue: whole blood diagnosis: healthy control treatment: n/a 1.814453106
GSM4548692 volunteer-10 tissue: whole blood diagnosis: healthy control treatment: n/a 1.790396438
GSM4548693 volunteer-11 tissue: whole blood diagnosis: healthy control treatment: n/a 1.600711909
GSM4548694 volunteer-12 tissue: whole blood diagnosis: healthy control treatment: n/a 2.182870393
GSM4548695 volunteer-13 tissue: whole blood diagnosis: healthy control treatment: n/a 3.3522935
GSM4548696 volunteer-14 tissue: whole blood diagnosis: healthy control treatment: n/a 1.621313771
GSM4548697 volunteer-15 tissue: whole blood diagnosis: healthy control treatment: n/a 1.600508039
GSM4548698 volunteer-16 tissue: whole blood diagnosis: healthy control treatment: n/a 1.545270667
GSM4548699 volunteer-17 tissue: whole blood diagnosis: healthy control treatment: n/a 1.655403514
GSM4548700 volunteer-18 tissue: whole blood diagnosis: healthy control treatment: n/a 1.570525366
GSM4548701 volunteer-19 tissue: whole blood diagnosis: healthy control treatment: n/a 2.636325445
GSM4548702 volunteer-20 tissue: whole blood diagnosis: healthy control treatment: n/a 2.104566243
GSM4548703 volunteer-21 tissue: whole blood diagnosis: healthy control treatment: n/a 2.041641391
GSM4548704 volunteer-22 tissue: whole blood diagnosis: healthy control treatment: n/a 1.714868484
GSM4548705 volunteer-23 tissue: whole blood diagnosis: healthy control treatment: n/a 1.65584184
GSM4548706 volunteer-24 tissue: whole blood diagnosis: healthy control treatment: n/a 1.622355263
GSM4548707 volunteer-25 tissue: whole blood diagnosis: healthy control treatment: n/a 1.926501941
GSM4548708 patient-9 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.782097991
GSM4548709 patient-10 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 1.572486699
GSM4548710 patient-11 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 1.579257991
GSM4548711 patient-12 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.263110548
GSM4548712 patient-13 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.852833478
GSM4548713 patient-14 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.398319736
GSM4548714 patient-15 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.416722067
GSM4548715 patient-16 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 1.56207748
GSM4548716 patient-17 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 1.564222055
GSM4548717 patient-18 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 1.581798114
GSM4548718 patient-19 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.301732681
GSM4548719 patient-20 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.026426194
GSM4548720 patient-21 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 1.582963612
GSM4548721 patient-22 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.002863863
GSM4548722 patient-23 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 1.625333689
GSM4548723 patient-24 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 1.858686322
GSM4548724 patient-25 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.810684157
GSM4548725 treatment-1 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.935433225
GSM4548726 treatment-2 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.567048343
GSM4548727 treatment-3 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.562706735
GSM4548728 treatment-4 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.57491969
GSM4548729 treatment-5 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.648053152
GSM4548730 treatment-6 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.481430804
GSM4548731 treatment-7 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.213097344
GSM4548732 treatment-8 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.569345091
GSM4548733 treatment-9 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.600204812
GSM4548734 treatment-10 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.582963612
GSM4548735 treatment-11 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.593749196
GSM4548736 treatment-12 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.627699827
GSM4548737 treatment-13 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.658510914
GSM4548738 treatment-14 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.570348839
GSM4548739 treatment-15 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.571577569
GSM4548740 treatment-16 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.630425614
GSM4548741 treatment-17 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.930286225
GSM4548742 treatment-18 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.602520207
GSM4548743 treatment-19 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.722444247
GSM4548744 treatment-20 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.566207632
GSM4548745 treatment-21 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.575991799
GSM4548746 treatment-22 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.902778904
GSM4548747 treatment-23 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.886999337
GSM4548748 treatment-24 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.53630719
GSM4548749 treatment-25 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.552458361

ID GSE166193
Title Expression data from human astrocytes (HA) under oxygen-glucose deprivation / reoxygenation
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM5065655 without DEX pretreatment, reoxygenation time is 0 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 0 h tissue: brain 5.71592
GSM5065656 without DEX pretreatment, reoxygenation time is 2 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 2 h tissue: brain 5.55883
GSM5065657 without DEX pretreatment, reoxygenation time is 6 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 6 h tissue: brain 5.41619
GSM5065658 without DEX pretreatment, reoxygenation time is 12 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 12 h tissue: brain 5.50442
GSM5065659 without DEX pretreatment, reoxygenation time is 24 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 24 h tissue: brain 5.39438
GSM5065660 with DEX pretreatment, reoxygenation time is 0 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 0 h tissue: brain 5.39829
GSM5065661 with DEX pretreatment, reoxygenation time is 2 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 2 h tissue: brain 5.81789
GSM5065662 with DEX pretreatment, reoxygenation time is 6 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 6 h tissue: brain 5.58206
GSM5065663 with DEX pretreatment, reoxygenation time is 12 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 12 h tissue: brain 5.28161
GSM5065664 with DEX pretreatment, reoxygenation time is 24 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 24 h tissue: brain 5.25336
GSM5065665 control cell type: astrocyte treatment: without stress tissue: brain 5.25486

ID GSE179004
Title Expression data from glioblastoma surgical specimens
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM5403447 glioblastoma tissue 1 in TIVA group tissue: glioblastoma 2.312265856
GSM5403448 glioblastoma tissue 2 in TIVA group tissue: glioblastoma 1.92732521
GSM5403449 glioblastoma tissue 3 in TIVA group tissue: glioblastoma 2.287420201
GSM5403450 glioblastoma tissue 1 in INHA group tissue: glioblastoma 2.380697215
GSM5403451 glioblastoma tissue 2 in INHA group tissue: glioblastoma 2.722096753
GSM5403452 glioblastoma tissue 3 in INHA group tissue: glioblastoma 2.599780953

ID GSE212044
Title Reversibility of etomidate-induced contractile arrest through activation of myocardial autophagy
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM6508421 IPSC-CM cells, DSMO 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 15.0
GSM6508422 IPSC-CM cells, DSMO 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 14.0
GSM6508423 IPSC-CM cells, DSMO 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 14.0
GSM6508424 IPSC-CM cells, Etomidate 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 10.0
GSM6508425 IPSC-CM cells, Etomidate 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 0.0
GSM6508426 IPSC-CM cells, Etomidate 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 17.0
GSM6508427 IPSC-CM cells, Propofol 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 3.0
GSM6508428 IPSC-CM cells, Propofol 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 11.0
GSM6508429 IPSC-CM cells, Propofol 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 2.0

ID GSE255952
Title Transcriptome data of B cells and T helper cells from patients with multiple sclerosis receiving methylprednisolone for the treatment of an acute relapse
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM8083291 patient C1P1, before first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 34.9 cells per ml: 2982000 purity (%): 98.1 rna integrity number: 7.8 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss 3.90255
GSM8083292 patient C1P1, after first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 25.9 cells per ml: 304500 purity (%): 95.3 rna integrity number: 8.7 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss 3.90589
GSM8083293 patient C1P1, before second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.8 cells per ml: 1254750 purity (%): 96.7 rna integrity number: 8.3 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea 3.80344
GSM8083294 patient C1P1, after second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.6 cells per ml: 231000 purity (%): 93.7 rna integrity number: 9.4 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea 3.72418
GSM8083295 patient C1P2, before first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 4.7 cells per ml: 236250 purity (%): 91.9 rna integrity number: 9.0 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.33604
GSM8083296 patient C1P2, after first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 3.7 cells per ml: 283500 purity (%): 91.0 rna integrity number: 9.1 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.16941
GSM8083297 patient C1P2, before first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 28.7 cells per ml: 693000 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.64461
GSM8083298 patient C1P2, after first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.5 cells per ml: 624750 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.41521
GSM8083299 patient C1P3, before first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 10.0 cells per ml: 498750 purity (%): 98.8 rna integrity number: 8.9 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.45877
GSM8083300 patient C1P3, after first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.7 cells per ml: 383250 purity (%): 97.9 rna integrity number: 9.4 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.34842
GSM8083301 patient C1P3, before first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 31.0 cells per ml: 1134000 purity (%): 94.7 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.82465
GSM8083302 patient C1P3, after first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 18.1 cells per ml: 640500 purity (%): 96.2 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.48854
GSM8083303 patient C1P3, before second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 30.3 cells per ml: 897750 purity (%): 97.0 rna integrity number: 8.5 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp 3.7809
GSM8083304 patient C1P3, after second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.7 cells per ml: 1433250 purity (%): 97.5 rna integrity number: 8.3 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 5 side effects to mp: none 3.68542
GSM8083305 patient C1P4, before first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.3 cells per ml: 378000 purity (%): 96.3 rna integrity number: 9.6 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.09985
GSM8083306 patient C1P4, after first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.5 cells per ml: 939750 purity (%): 96.7 rna integrity number: 8.8 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.38091
GSM8083307 patient C1P4, before first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 38.1 cells per ml: 1522500 purity (%): 98.7 rna integrity number: NA age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.00245
GSM8083308 patient C1P4, after first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 15.9 cells per ml: 1617000 purity (%): 98.3 rna integrity number: 8.5 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.56364
GSM8083309 patient C1P5, before first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 31.6 cells per ml: 1344000 purity (%): 99.1 rna integrity number: 8.0 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none 3.77758
GSM8083310 patient C1P5, after first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 21.9 cells per ml: 1165500 purity (%): 98.9 rna integrity number: 8.4 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none 3.82355
GSM8083311 patient C1P5, before second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 26.9 cells per ml: 1233750 purity (%): 97.8 rna integrity number: 8.5 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems 3.63119
GSM8083312 patient C1P5, after second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.0 cells per ml: 514500 purity (%): 98.6 rna integrity number: 8.7 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems 3.65603
GSM8083313 patient C2P1, before first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 11.7 cells per ml: 2604000 purity (%): 96.7 rna integrity number: 8.5 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.19553
GSM8083314 patient C2P1, after first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 8.8 cells per ml: 630000 purity (%): 97.4 rna integrity number: 8.4 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.7941
GSM8083315 patient C2P1, before first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 41.5 cells per ml: 2436000 purity (%): 94.6 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.67597
GSM8083316 patient C2P1, after first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.2 cells per ml: 346500 purity (%): 86.5 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.45721
GSM8083317 patient C2P2, before first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.9 cells per ml: 467250 purity (%): 87.3 rna integrity number: 8.8 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.54484
GSM8083318 patient C2P2, after first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.3 cells per ml: 199500 purity (%): 97.6 rna integrity number: 9.5 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: 1.5 disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.40853
GSM8083319 patient C2P3, before first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.61424
GSM8083320 patient C2P3, after first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.63582
GSM8083321 patient C2P3, before first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 20.2 cells per ml: 1711500 purity (%): 94.3 rna integrity number: 7.3 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.64686
GSM8083322 patient C2P3, after first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 22.8 cells per ml: 992250 purity (%): 96.5 rna integrity number: 8.2 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.43451
GSM8083323 patient C2P4, before first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 8.0 cells per ml: 1690500 purity (%): 96.3 rna integrity number: 9.0 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.68307
GSM8083324 patient C2P4, after first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 2.2 cells per ml: 273000 purity (%): 93.0 rna integrity number: 8.3 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.79891
GSM8083325 patient C2P5, before first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.6 cells per ml: 136500 purity (%): 53.8 rna integrity number: 6.9 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.53374
GSM8083326 patient C2P5, after first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.8 cells per ml: 687750 purity (%): 98.1 rna integrity number: 8.2 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.49264
GSM8083327 patient C2P6, before first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 4.2 cells per ml: 546000 purity (%): 92.4 rna integrity number: 8.8 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: 6.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.65627
GSM8083328 patient C2P6, after first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 6.6 cells per ml: 714000 purity (%): 97.8 rna integrity number: 9.0 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: NA disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.52015
GSM8083329 patient C2P7, before first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.7 cells per ml: 215250 purity (%): 95.6 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: yes fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none 3.39172
GSM8083330 patient C2P7, after first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.8 cells per ml: 162750 purity (%): 93.2 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: better fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none 3.28478
GSM8083331 patient C2P8, before first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 3.5 cells per ml: 220500 purity (%): 95.5 rna integrity number: 8.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.24887
GSM8083332 patient C2P8, after first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 11.0 cells per ml: 535500 purity (%): 97.3 rna integrity number: 7.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.50298
GSM8083333 patient C3P1, before second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 24.0 cells per ml: 225750 purity (%): 97.0 rna integrity number: 7.9 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: yes total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none 3.85918
GSM8083334 patient C3P1, after second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 10.1 cells per ml: 315000 purity (%): 98.6 rna integrity number: 8.3 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: worse total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none 4.03074
GSM8083335 patient C4P1, before first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 5.3 cells per ml: 336000 purity (%): 96.3 rna integrity number: 9.4 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis 3.44657
GSM8083336 patient C4P1, after first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.9 cells per ml: 1417500 purity (%): 96.1 rna integrity number: 8.7 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis 3.18841
GSM8083337 patient C4P2, before first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: NA cells per ml: 493500 purity (%): 94.2 rna integrity number: 8.2 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 7.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: yes fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.37277
GSM8083338 patient C4P2, after first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.4 cells per ml: 236250 purity (%): 42.7 rna integrity number: 8.1 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 6.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.63462

ID GSE4386
Title Transcriptomics in cardiac surgery
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM99229 H01_S_B1 male CABG patient, atrial tissue baseline before CABG surgery 4.9463176635
GSM99235 H01_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 5.817013507
GSM99239 H02_P_B1 male CABG patient, atrial tissue baseline before CABG surgery 7.379627317999999
GSM99241 H02_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.9535947035
GSM99244 H03_P_B1 male CABG patient, atrial tissue baseline before CABG surgery 4.914996610999999
GSM99246 H03_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.915762733999999
GSM99247 H04_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.8288752735
GSM99249 H04_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.8896321789999995
GSM99252 H05_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.9152096929999995
GSM99253 H05_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.838530849
GSM99255 H06_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.975723985
GSM99257 H06_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.9152846455
GSM99258 H07_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.765903338999999
GSM99259 H07_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.898806737999999
GSM99261 H08_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.920450300000001
GSM99265 H08_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.893494175000001
GSM99268 H09_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.868533998
GSM99271 H09_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 6.486542297
GSM99274 H10_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 5.0668056895
GSM99277 H10_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 5.022779236
GSM99280 H11_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.6780780315
GSM99282 H11_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.7845970399999995
GSM99285 H12_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.9498650645
GSM99287 H12_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 5.003356027000001
GSM99289 H13_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.862875969499999
GSM99290 H13_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.9697753764999995
GSM99291 H14_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.921255658
GSM99292 H14_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.929206220999999
GSM99293 H15_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.914607891
GSM99294 H15_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 5.1002778939999995
GSM99295 H16_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 5.0009756405
GSM99296 H16_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 5.070001845
GSM99298 H17_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.843619278
GSM99299 H17_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.887685522
GSM99301 H18_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.963595624
GSM99302 H18_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.936037375
GSM99303 H19_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.8510664505
GSM99304 H19_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.9266638745
GSM99305 H20_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.789484088
GSM99306 H20_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.767095881

ID GSE56256
Title Influence of hexafluoro-2-propanol (HFIP) on lipopolysaccharides-induced inflammation in human microvascular endothelial cells of the lung
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM1357752 7_HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs 6.6830394
GSM1357753 8_HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs 47.65787
GSM1357754 9_HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs 7.6488761
GSM1357755 4_LPS cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs 5.8338575
GSM1357756 5_LPS cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs 88.283637
GSM1357757 6_LPS cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs 6.1511451
GSM1357758 11_LPS-HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL and HFIP 8mmol/L over a time period of 6 hrs 6.7805909
GSM1357759 12_LPS-HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL and HFIP 8mmol/L over a time period of 6 hrs 5.374931200000001
GSM1357760 1_PBS cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs 6.495838600000001
GSM1357761 2_PBS cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs 7.1526276
GSM1357762 3_PBS cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs 6.824724000000001

ID GSE59526
Title Affymetrix Chip data of the transcriptome of human clinical study for acupuncture mechanisms on rheumatoid arthritis
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM1438864 Peripheral blood mononuclear cells from AP group, Patient 2 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 53 treatment group: acupuncture+methotrexate time point: before therapy patient id: 2 13.256096119999999
GSM1438865 Peripheral blood mononuclear cells from AP group, Patient 3 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 48 treatment group: acupuncture+methotrexate time point: before therapy patient id: 3 8.220280832
GSM1438866 Peripheral blood mononuclear cells from AP group, Patient 6 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 36 treatment group: acupuncture+methotrexate time point: before therapy patient id: 6 30.876506585
GSM1438867 Peripheral blood mononuclear cells from AP group, Patient 8 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 60 treatment group: acupuncture+methotrexate time point: before therapy patient id: 8 14.644791715
GSM1438868 Peripheral blood mononuclear cells from AP group, Patient 9 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 31 treatment group: acupuncture+methotrexate time point: before therapy patient id: 9 9.2623609695
GSM1438869 Peripheral blood mononuclear cells from MTX group, Patient 4 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 61 treatment group: methotrexate time point: before therapy patient id: 4 10.379072595
GSM1438870 Peripheral blood mononuclear cells from MTX group, Patient 5 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 49 treatment group: methotrexate time point: before therapy patient id: 5 9.660417592
GSM1438871 Peripheral blood mononuclear cells from MTX group, Patient 7 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 35 treatment group: methotrexate time point: before therapy patient id: 7 10.777775745
GSM1438872 Peripheral blood mononuclear cells from Patient 1 after 2 weeks acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 64 treatment group: acupuncture+methotrexate time point: after 2 weeks therapy patient id: 1 14.053617165
GSM1438873 Peripheral blood mononuclear cells from Patient 3 after 2 weeks acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 48 treatment group: acupuncture+methotrexate time point: after 2 weeks therapy patient id: 3 10.897920028000001
GSM1438874 Peripheral blood mononuclear cells from Patient 1 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 64 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 1 9.3500157015
GSM1438875 Peripheral blood mononuclear cells from Patient 2 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 53 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 2 9.1924397115
GSM1438876 Peripheral blood mononuclear cells from Patient 6 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 36 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 6 12.375717675
GSM1438877 Peripheral blood mononuclear cells from Patient 8 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 60 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 7.2566775045
GSM1438878 Peripheral blood mononuclear cells from Patient 9 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 31 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 9 11.9405986815
GSM1438879 Peripheral blood mononuclear cells from Patient 4 after 3 months MTX therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 61 treatment group: methotrexate time point: after 3 months therapy patient id: 4 14.542822395
GSM1438880 Peripheral blood mononuclear cells from Patient 5 after 3 months MTX therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 49 treatment group: methotrexate time point: after 3 months therapy patient id: 5 12.922858688000002
GSM1438881 Peripheral blood mononuclear cells from Patient 7 after 3 months MTX therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 35 treatment group: methotrexate time point: after 3 months therapy patient id: 7 31.066759644999998